Related references
Note: Only part of the references are listed.Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2021)
Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis Results From a Phase 2a Clinical Trial
Einat Almon et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2021)
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner et al.
GASTROENTEROLOGY (2021)
Advances in Oral Drug Delivery
Mohammed S. Alqahtani et al.
FRONTIERS IN PHARMACOLOGY (2021)
From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative
Ajay M Verma et al.
Lancet Gastroenterology & Hepatology (2021)
Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges
Amanda Cano et al.
JOURNAL OF NANOBIOTECHNOLOGY (2021)
Encapsulation of Active Pharmaceutical Ingredients in Lipid Micro/Nanoparticles for Oral Administration by Spray-Cooling
Carmen S. Favaro-Trindade et al.
PHARMACEUTICS (2021)
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease
Walter Reinisch et al.
INFLAMMATORY BOWEL DISEASES (2021)
ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
Joana Torres et al.
JOURNAL OF CROHNS & COLITIS (2020)
SLN and NLC for topical, dermal, and transdermal drug delivery
Eliana B. Souto et al.
EXPERT OPINION ON DRUG DELIVERY (2020)
New Nanotechnologies for the Treatment and Repair of Skin Burns Infections
Eliana B. Souto et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Emerging treatments for inflammatory bowel disease
Karl Hazel et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2020)
The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
Sudabeh Alatab et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2020)
Analytical tools and evaluation strategies for nanostructured lipid carrier-based topical delivery systems
Sheefali Mahant et al.
EXPERT OPINION ON DRUG DELIVERY (2020)
Anti-TNF-α Agents in Inflammatory Bowel Disease and Course of COVID-19
Antonio Tursi et al.
INFLAMMATORY BOWEL DISEASES (2020)
Management of IBD during the COVID-19 outbreak: resetting clinical priorities
Silvio Danese et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2020)
Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
Bahez Gareb et al.
PHARMACEUTICS (2020)
Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model
Jung Min Kim et al.
JOURNAL OF NANOBIOTECHNOLOGY (2020)
Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
Anja St Clair-Jones et al.
RHEUMATOLOGY AND THERAPY (2020)
IgA as a potential candidate for enteric monoclonal antibody therapeutics with improved gastrointestinal stability
Aaron L. Wallace et al.
VACCINE (2020)
Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy
Xinyu Wang et al.
THERANOSTICS (2020)
Adapting liposomes for oral drug delivery
Haisheng He et al.
ACTA PHARMACEUTICA SINICA B (2019)
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Surface-tailored anti-HER2/neu-solid lipid nanoparticles for site-specific targeting MCF-7 and BT-474 breast cancer cells
Eliana B. Souto et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2019)
Infliximab in inflammatory bowel disease
Konstantinos Papamichael et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2019)
Key production parameters for the development of solid lipid nanoparticles by high shear homogenization
Eliana B. Souto et al.
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY (2019)
Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process
Bahez Gareb et al.
PHARMACEUTICS (2019)
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients
Suhail Nurbhai et al.
SCIENTIFIC REPORTS (2019)
Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys
J. Scott Crowe et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2019)
Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study
Johan Burisch et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis
Elisa K. Boden et al.
CROHNS & COLITIS 360 (2019)
Bromelain-loaded nanoparticles: A comprehensive review of the state of the art
Janaina Artem Ataide et al.
ADVANCES IN COLLOID AND INTERFACE SCIENCE (2018)
Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease
J. Scott Crowe et al.
SCIENTIFIC REPORTS (2018)
Nano based drug delivery systems: recent developments and future prospects
Jayanta Kumar Patra et al.
JOURNAL OF NANOBIOTECHNOLOGY (2018)
Immunogenicity of biologics in inflammatory bowel disease
Severine Vermeire et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
A plant cell-expressed recombinant anti-TNF fusion protein is biologically active in the gut and alleviates immune-mediated hepatitis and colitis
Yaron Ilan et al.
IMMUNOBIOLOGY (2017)
Enhancing biopharmaceutical attributes of phospholipid complex-loaded nanostructured lipidic carriers of mangiferin: Systematic development, characterization and evaluation
Rajneet Kaur Khurana et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Formulation and development of orodispersible sustained release tablet of domperidone
Hemlata G. Patil et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2016)
Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation
Slavomira Doktorovova et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2016)
Gastrointestinal stability of therapeutic anti-TNF α IgG1 monoclonal antibodies
Vipul Yadav et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Development and potential application of an oral ColoPulse infliximab tablet with colon specific release: A feasibility study
Jacoba M. Maurer et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2016)
Lipid-associated oral delivery: Mechanisms and analysis of oral absorption enhancement
Oljora Rezhdo et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis
Deborah S. Hartman et al.
JOURNAL OF CROHNS & COLITIS (2016)
AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial
M. Scott Harris et al.
JOURNAL OF CROHNS & COLITIS (2016)
Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis
Yaron Ilan et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches
Seth Amidon et al.
AAPS PHARMSCITECH (2015)
Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers - A systematic review of in vitro data
[Anonymous]
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2014)
Advances in brain drug targeting and delivery: limitations and challenges of solid lipid nanoparticles
Medha Patel et al.
EXPERT OPINION ON DRUG DELIVERY (2013)
AVX-470: A Novel Oral Anti-TNF Antibody with Therapeutic Potential in Inflammatory Bowel Disease
Kailash C. Bhol et al.
INFLAMMATORY BOWEL DISEASES (2013)
Oral lipid-based drug delivery systems an overview
Sandeep Kalepu et al.
ACTA PHARMACEUTICA SINICA B (2013)
Bioadhesive pellets increase local 5-aminosalicylic acid concentration in experimental colitis
Tereza Bautzova et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2012)
An Oral CD3-Specific Antibody Suppresses T-Cell-Induced Colitis and Alters Cytokine Responses to T-Cell Activation in Mice
Katharina Forster et al.
GASTROENTEROLOGY (2012)
Solid lipid nanoparticles as intracellular drug transporters: An investigation of the uptake mechanism and pathway
S. Martins et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2012)
Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery
Patricia Severino et al.
JOURNAL OF DRUG DELIVERY (2012)
Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages
Raja Atreya et al.
GASTROENTEROLOGY (2011)
Oral Administration of OKT3 Monoclonal Antibody to Human Subjects Induces a Dose-Dependent Immunologic Effect in T Cells and Dendritic Cells
Yaron Ilan et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2010)
Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis
K. Vandenbroucke et al.
MUCOSAL IMMUNOLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products
Jana Pardeike et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2009)
Formulation, antimalarial activity and biodistribution of oral lipid nanoemulsion of primaquine
Kamalinder K. Singh et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2008)
Cosmetic features and applications of lipid nanoparticles (SLN®, NLC®)
E. B. Souto et al.
INTERNATIONAL JOURNAL OF COSMETIC SCIENCE (2008)
Lipid nanoparticles (SLN®, NLC®) for cutaneous drug delivery:: Structure, protection and skin effects
E. B. Souto et al.
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY (2007)
Solid lipid nanoparticles as a drug delivery system for peptides and proteins
Antonio J. Almeida et al.
ADVANCED DRUG DELIVERY REVIEWS (2007)
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25-LAP+ T cells
Hirofumi Ochi et al.
NATURE MEDICINE (2006)
Development of enteric-coated timed-release matrix tablets for colon targeting
J Alvarez-Fuentes et al.
JOURNAL OF DRUG TARGETING (2004)
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery
EB Souto et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2004)
Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines
RAJ Ransford et al.
GUT (2002)
Share Paper
